<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37326666</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol Int</ISOAbbreviation></Journal><ArticleTitle>Refractory systemic lupus erythematosus with chylous effusion successfully treated with sirolimus: a case report and literature review.</ArticleTitle><Pagination><StartPage>1743</StartPage><EndPage>1749</EndPage><MedlinePgn>1743-1749</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-023-05363-w</ELocationID><Abstract><AbstractText>Chylous effusion is a rare manifestation of systemic lupus erythematosus (SLE). When it does occur in SLE, it is generally well treated with standard pharmacologic or surgical measures. We present a decade of management in a case of SLE with lung affliction and development of refractory bilateral chylous effusion and pulmonary arterial hypertension (PAH). In the first years, the patient was treated under a Sjogren syndrome diagnose. After few years, her respiratory condition worsened due to chylous effusion and PAH. Immunosuppression therapy (methylprednisolone) was reintroduced, and vasodilator therapy commenced. With this, her cardiac function remained stable, but respiratory function continuously worsened despite several therapy trials with different combinations of immunosuppressant (glucocorticoids, resochin, cyclophosphamide and mycophenolate mofetil). On top of pleural effusion worsening, the patient developed ascites and severe hypoalbuminaemia. Even though albumin loss was stabilized with monthly octreotide applications, the patient remained respiratory insufficient and in need of continuous oxygen therapy. At that point, we decided to introduce sirolimus on top of glucocorticoids and mycophenolate mofetil therapy. Her clinical status, radiological finding, and lung function gradually improved and she became respiratory sufficient at rest. The patient remains in our follow-up and has been stable on given therapy for over 3&#xa0;years despite overcoming a severe COVID-19 pneumonia in 2021. This case adds to the body of evidence of sirolimus effectiveness in patients with refractory systemic lupus and is, to our best knowledge, the first case to report its successful application in a patient with SLE and refractory chylous effusion.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Banic</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6198-7123</Identifier><AffiliationInfo><Affiliation>Department of Lung Diseases Jordanovac, University Hospital Centre Zagreb, Jordanovac 104, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavlisa</LastName><ForeName>G</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7162-7212</Identifier><AffiliationInfo><Affiliation>Department of Lung Diseases Jordanovac, University Hospital Centre Zagreb, Jordanovac 104, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hecimovic</LastName><ForeName>A</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3632-0896</Identifier><AffiliationInfo><Affiliation>Department of Lung Diseases Jordanovac, University Hospital Centre Zagreb, Jordanovac 104, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University of Zagreb, Salata 2, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grzelja</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, University Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anic</LastName><ForeName>B</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4940-0577</Identifier><AffiliationInfo><Affiliation>Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital Centre Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University of Zagreb, Salata 2, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samarzija</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5303-9353</Identifier><AffiliationInfo><Affiliation>Department of Lung Diseases Jordanovac, University Hospital Centre Zagreb, Jordanovac 104, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University of Zagreb, Salata 2, 10000, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jankovic Makek</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0171-764X</Identifier><AffiliationInfo><Affiliation>Department of Lung Diseases Jordanovac, University Hospital Centre Zagreb, Jordanovac 104, 10000, Zagreb, Croatia. mateja.jankovic@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University of Zagreb, Salata 2, 10000, Zagreb, Croatia. mateja.jankovic@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chylothorax</Keyword><Keyword MajorTopicYN="N">Siriolimus</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>11</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37326666</ArticleId><ArticleId IdType="doi">10.1007/s00296-023-05363-w</ArticleId><ArticleId IdType="pii">10.1007/s00296-023-05363-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wiedemann HP, Matthay RA (1992) Pulmonary manifestations of systemic lupus erythematosus. J Thorac Imaging 7:1&#x2013;18. https://doi.org/10.1097/00005382-199203000-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005382-199203000-00003</ArticleId><ArticleId IdType="pubmed">1578522</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi BY, Yoon MJ, Shin K et al (2015) Characteristics of pleural effusions in systemic lupus erythematosus: differential diagnosis of lupus pleuritis. Lupus 24:321&#x2013;326. https://doi.org/10.1177/0961203314555171</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314555171</ArticleId><ArticleId IdType="pubmed">25318967</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudrappa M, Paul M (2023) Chylothorax. StatPearls Publishing</Citation></Reference><Reference><Citation>Rehman KU, Sivakumar P (2022) Non-traumatic chylothorax: diagnostic and therapeutic strategies. Breathe 18:210163. https://doi.org/10.1183/20734735.0163-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/20734735.0163-2021</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G-H, Zhang L-L, Wang Y-H, Shen W-B (2020) Clinical characteristics of systemic lupus erythematosus with chylothorax and/or chylous ascites. Medicine 99:e23661. https://doi.org/10.1097/MD.0000000000023661</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023661</ArticleId><ArticleId IdType="pubmed">33371102</ArticleId><ArticleId IdType="pmc">7748198</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng L, Wu C, Hong R et al (2020) Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis. Ther Adv Musculoskelet Dis. https://doi.org/10.1177/1759720X20953336</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X20953336</ArticleId><ArticleId IdType="pubmed">33240406</ArticleId><ArticleId IdType="pmc">7675870</ArticleId></ArticleIdList></Reference><Reference><Citation>Song P, Zhang J, Shang C, Zhang L (2019) Refractory chylous pleural effusion with systemic lupus erythematosus. Z Rheumatol 78:797&#x2013;802. https://doi.org/10.1007/s00393-018-0545-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00393-018-0545-z</ArticleId><ArticleId IdType="pubmed">30276728</ArticleId></ArticleIdList></Reference><Reference><Citation>Majed HI, Nabil MT, Juahar I, Mohammed JA (2022) Chylothorax as a rare manifestation of systemic lupus erythematosus flare up&#x2014;case study. Rheumatology (Bulgaria). https://doi.org/10.35465/30.1.2022.pp90-94</Citation><ArticleIdList><ArticleId IdType="doi">10.35465/30.1.2022.pp90-94</ArticleId></ArticleIdList></Reference><Reference><Citation>Starobin D, Guller V, Gurevich A, Tal S (2017) Minocycline induced lupus with yellow colored chylous exudative pleural effusion. Respir Med Case Rep 22:113&#x2013;116. https://doi.org/10.1016/j.rmcr.2017.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmcr.2017.07.005</ArticleId><ArticleId IdType="pubmed">28761807</ArticleId><ArticleId IdType="pmc">5524223</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahan BD (2000) Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 356:194&#x2013;202. https://doi.org/10.1016/S0140-6736(00)02480-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)02480-6</ArticleId><ArticleId IdType="pubmed">10963197</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon H-Y, Hwang JJ, Kim DS, Song JW (2018) Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis. Orphanet J Rare Dis 13:204. https://doi.org/10.1186/s13023-018-0946-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-018-0946-8</ArticleId><ArticleId IdType="pubmed">30428897</ArticleId><ArticleId IdType="pmc">6236936</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll GA, Kokolo MB, Mallick R et al (2014) Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 349:g6679&#x2013;g6679. https://doi.org/10.1136/bmj.g6679</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g6679</ArticleId><ArticleId IdType="pubmed">25422259</ArticleId><ArticleId IdType="pmc">4241732</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen LS, Vautier M, Allenbach Y et al (2019) Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation. Drug Saf. https://doi.org/10.1007/s40264-019-00810-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-019-00810-9</ArticleId><ArticleId IdType="pubmed">31111340</ArticleId><ArticleId IdType="pmc">7048703</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan B, Qazi Y, Wellen JR (2014) Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev 28:126&#x2013;133. https://doi.org/10.1016/j.trre.2014.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trre.2014.03.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736&#x2013;745. https://doi.org/10.1136/annrheumdis-2019-215089</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Z-W, Kelly R, Winans T et al (2018) Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet 391:1186&#x2013;1196. https://doi.org/10.1016/S0140-6736(18)30485-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30485-9</ArticleId><ArticleId IdType="pubmed">29551338</ArticleId><ArticleId IdType="pmc">5891154</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez D, Bonilla E, Mirza N et al (2006) Rapamycin reduces disease activity and normalizes T cell activation&#x2013;induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 54:2983&#x2013;2988. https://doi.org/10.1002/art.22085</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22085</ArticleId><ArticleId IdType="pubmed">16947529</ArticleId><ArticleId IdType="pmc">4034146</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez DR, Telarico T, Bonilla E et al (2009) Activation of mammalian target of rapamycin controls the loss of TCR&#x3b6; in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol 182:2063&#x2013;2073. https://doi.org/10.4049/jimmunol.0803600</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0803600</ArticleId><ArticleId IdType="pubmed">19201859</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson P, Wallin P, Sj&#xf6;wall C (2019) Clinical experience of sirolimus regarding efficacy and safety in systemic lupus erythematosus. Front Pharmacol 10:1&#x2013;9. https://doi.org/10.3389/fphar.2019.00082</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.00082</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap DYH, Tang C, Chan GCW et al (2018) Longterm data on sirolimus treatment in patients with lupus nephritis. J Rheumatol 45:1663&#x2013;1670. https://doi.org/10.3899/jrheum.180507</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.180507</ArticleId><ArticleId IdType="pubmed">30275264</ArticleId></ArticleIdList></Reference><Reference><Citation>Piranavan P, Perl A (2021) Improvement of renal and non-renal SLE outcome measures on sirolimus therapy&#x2014;a 21-year follow-up study of 73 patients. C1 Immunol 229:108781. https://doi.org/10.1016/j.clim.2021.108781</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108781</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Wang Q, Xu D et al (2021) Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. Rheumatology 60:2629&#x2013;2634. https://doi.org/10.1093/rheumatology/keaa645</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa645</ArticleId><ArticleId IdType="pubmed">33200217</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley LE, Ataya A (2019) Clinical approach and review of causes of a chylothorax. Respir Med 157:7&#x2013;13. https://doi.org/10.1016/j.rmed.2019.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2019.08.014</ArticleId><ArticleId IdType="pubmed">31454675</ArticleId></ArticleIdList></Reference><Reference><Citation>Soysal DE, Hizar Turan S, Ozmen M et al (2013) A rare case of systemic lupus erythematosus with chylous ascites and chylothorax. Case Rep Rheumatol 2013:1&#x2013;3. https://doi.org/10.1155/2013/797696</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/797696</ArticleId></ArticleIdList></Reference><Reference><Citation>Bride KL, Vincent T, Smith-Whitley K et al (2016) Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood 127:17&#x2013;28. https://doi.org/10.1182/blood-2015-07-657981</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-07-657981</ArticleId><ArticleId IdType="pubmed">26504182</ArticleId><ArticleId IdType="pmc">4705607</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevacqua M, Baldo F, Pastore S et al (2019) Off-label use of sirolimus and everolimus in a pediatric center: a case series and review of the literature. Pediatr Drugs 21:185&#x2013;193. https://doi.org/10.1007/s40272-019-00337-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40272-019-00337-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K, Urowitz MB (2017) Cardiovascular and pulmonary manifestations of systemic lupus erythematosus. Curr Rheumatol Rev. https://doi.org/10.2174/1573397113666170704102444</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573397113666170704102444</ArticleId><ArticleId IdType="pubmed">28675998</ArticleId></ArticleIdList></Reference><Reference><Citation>Aithala R, Alex AG, Danda D (2017) Pulmonary hypertension in connective tissue diseases: an update. Int J Rheum Dis 20:5&#x2013;24. https://doi.org/10.1111/1756-185X.13001</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13001</ArticleId><ArticleId IdType="pubmed">28205373</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhala A (2012) Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol 2012:854941. https://doi.org/10.1155/2012/854941</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/854941</ArticleId><ArticleId IdType="pubmed">22489252</ArticleId><ArticleId IdType="pmc">3318206</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>